De novo lipogenesis predicts short-term body-composition response by bioelectrical impedance analysis to oral nutritional supplements in HIV- associated wasting

American Journal of Clinical Nutrition

Volumn 68, Issue 1, 1998, Pages 154-163

  Hoh, Rebecca ^b   Pelfini, Andrew ^b   Neese, Richard A ^b   Chan, Mary ^b   Cello, John P ^b   Cope, Frederick O ^b   Abbruzese, Bonnie C ^b   Richards, Ernie W ^b   Courtney, Kecia ^b   Hellerstein, Marc K ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

AIDS wasting; De novo lipogenesis; Enteral supplementation; Fat free mass; Gastrointestinal symptoms; Humans; Mass spectrometry; Peptide formula

Indexed keywords

SOMATOMEDIN;

ADULT; ARTICLE; BIOENERGY; BODY COMPOSITION; CALORIC INTAKE; CLINICAL ARTICLE; DIET SUPPLEMENTATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; LIPOGENESIS; MALE; MASS SPECTROMETRY; PREDICTION; PROTEIN ANALYSIS; PROTEIN BINDING; WASTING SYNDROME; WEIGHT REDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031750284     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/68.1.154     Document Type: Article

References (50)

1. Serwadda D, Sewankambo NK, Carswell JW, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 1985;2:849-52.
2. Grunfeld C, Feingold K. Metabolic disturbances in AIDS-wasting syndrome. N Engl J Med 1992;327:329-37.
3. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of bodycell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444-7.
4. Suttman U, Ockenga J, Seiberg O, Hoogestraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr 1995;8:239-46.
5. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutri 1985;42:1255-65.
6. Hellerstein MK. Nutritional and endocrine consequences of HIV infection. In: Crowe S, Hoy J, Mills J, eds. Management of the HIV-infected patient. New York: Cambridge University Press, 1996;194-205.
7. Hellerstein MK, Kahan J, Mudie H, Viteri F. Current approach to the treatment of HIV associated weight loss: pathophysiologic considerations and a preliminary report on a double-blind placebo-controlled trial of megestrol acetate. Semin Oncol 1990;17(suppl 9):17-33.
8. Kotler DP, Tierney AR, Culpeppermorgan JA, et al. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 1990;14:454-8.
9. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-9.
10. Oster MH, Enders SH, Samuels ST, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121:400-8.
11. Shike M, Russell DM, Detsky AS, et al. Changes in body composition in patients with small cell lung cancer. The effect of TPN as an adjunt to chemotherapy. Ann Intern Med 1984;101:303-9.
12. Cohn S, Vartsky D, Vaswani AN, et al. Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer 1982;4:107-19.
13. Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma 1987;27:262-6.
14. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wong J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
15. Hellersten MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;76:559-65.
16. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating Interferon levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-62.
17. Melchior JC, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991;53:437-41.
18. Hommes MJT, Romijn JA, Enden E, Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-ínfected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr 1991;54:311-5.
19. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992;55:455-60.
20. Mulligan K, Grunfeld C, Hellerstein MK, Neese R, Schambelan M. Anabolic effects of recombinant growth hormone in patients with weight loss associated with HIV infection. J Clin Endocrinol Metab 1993;77:956-62.
21. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR. Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;101:421-8.
22. McArdle H, Reid EC, Laplante MP, Freeman CR. Prophlaxis against radiation injury. The use of elemental diet prior to and during radiotherapy for invasive bladder cancer and in early post-operative feeding following radical cystectomy and ileal conduit. Arch Surg 1986;121:879-85.
23. National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press, 1989.
24. Metropolitan Life Insurance Company. 1983 Height and weight tables. Stat Bull Metropol Insur Co 1984;64:2-9.
25. Harris JA, Benedict SG. A biometric study of basal metabolism. Washington, DC: Carnegie Institute of Washington, 1919. (Publication no. 279.)
26. Godfried MH, Romijn J, van der Poll T, et al. Soluble receptors for tumor necrosis factors are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection. Metabolism 1995;44:1564-9.
27. Oster MH, Fielder PJ, Levin N, Cronin MJ. Adaptation to the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. J Clin Invest 1995;95:2258-65.
28. Hellerstein MK, Schwarz J-M, Neese RA. Regulation of de novo hepatic lipogenesis in humans. Annu Rev Nutr 1996;16:523-67.
29. Hellerstein MK, Christiansen M, Kaempfer S, et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest 1991;87:1841-52.
30. Hellerstein MK, Wu K, Kaempfer S, Kletke C, Shackleton CHL. Sampling the lipogenic hepatic acetyl-CoA pool in vivo in the rat. Comparison of xenobiotic probe to values predicted from isotopomeric distribution in circulating lipids and measurement of lipogenesis and acetyl-CoA dilution. J Biol Chem 1991;266:10912-9.
31. Hellerstein MFC, Neese R. Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Physiol 1992;263:E988-1001.
32. Blackham M, Cesar D, Park O-J, et al. Effects of recombinant monokines on hepatic pyruvate dehydrogenase (PDH), PDH kinase, de novo lipogenesis and plasma triglycerides. Abolition by prior fasting. Biochem J 1992;284:129-35.
33. Strawford A, Neese R, Hoh R, et al. Clinical heterogeneity for metabolic and nutritional measures in AIDS-wasting syndrome (AWS) compared to HIV-negative controls. XIth International Conference on AIDS, 1996. Vancouver, Canada: Transcontinental Printing Inc, 1996.
34. Lukaski HC. Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 1987;46:537-56.
35. Feingold K, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987;80:184-90.
36. Park O-J, Cesar D, Faix D, Wu K, Shackleton CHL, Hellerstein MK. Mechanisms of fructose-induced hypertriglyceridemia in the rat: activation of hepatic pyruvate dehydrogenase (PDH) through inhibition of PDH kinase. Biochem J 1992;282:753-7.
37. Schwarz J-M, Neese RA, Turner SM, Nguyen C, Hellerstein MK. Effect of fructose ingestion on glucose production (GP) and de novo lipogenesis (DNL) in normal and hyperinsulinemic obese humans. Diabetes 1994;43(suppl l):52A(abstr).
38. Faix D, Neese RA, Kletke C, et al. Quantification of periodicities in menstrual and diurnal rates of cholesterol and fat synthesis in humans. J Lipid Res 1993;34:2063-75.
39. Neese RA, Benowitz NL, Hoh R, et al. Metabolic interations between surplus dietary energy intake and cigarette smoking or its cessation. Am J Physiol 1994;267:E1023-34.
40. Hellerstein MK, Schwarz J-M, Neese RA, et al. De novo hepatic lipogenesis (DNL) is a highly sensitive biomarker of energy balance in controlled dietary conditions in normal humans. Diabetes 1994;43(suppl l):48A(abstr).
41. Hellerstein MK. Methods for measurement of fatty acid and cholesterol metabolism. In: Howard B, Packard C, eds. Curr Opin Lipidol 1995;6:172-81.
42. Schwarz J-M, Neese RA, Turner S, Dare D, Hellerstein MK. Short-term alterations in carbohydrate energy intake in humans: striking effects on hepatic glucose production, de novo lipogenesis, lipolysis and whole-body fuel selection. J Clin Invest 1995;96:2735-43.
43. Hudgins L, Hellerstein M, Seidman C, Neese R, Diakun J, Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric, low-fat, high carbohydrate diet. J Clin Invest 1996;410:1064-8.
44. Hellerstein MK, Wu K, Kaempfer S, et al. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immunodeficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr 1996; 11:258-70.
45. Siler S, Neese R, Hellerstein MK. Effects of ethanol on lipolysis and de novo lipogenesis in humans. FASEB J 1996;10:A799(abstr).
46. Hellerstein MK. Synthesis of fat in response to alterations in diet: insights from new stable isotope methodologies. Lipids 1996;31:S117-25.
47. Godfried MH, van der Poll T, Jansen J, et al. Soluble receptors for tumor necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993;7:33-6.
48. Denke M, Grundy M. Individual responses to a cholesterol-lowering diet in 50 men with moderate hypercholesterolemia. Arch Intern Med 1994;154:317-25.
49. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333:83-8.
50. Grunfeld C. What causes wasting in AIDS? N Engl J Med 1995;333:123-4.